These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24217844)

  • 21. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biologic therapy and pregnancy outcomes in women with rheumatic diseases.
    Vinet E; Pineau C; Gordon C; Clarke AE; Bernatsky S
    Arthritis Rheum; 2009 May; 61(5):587-92. PubMed ID: 19404999
    [No Abstract]   [Full Text] [Related]  

  • 23. Rheumatoid arthritis: new developments in biologic therapy.
    Mahajan A; Sharma R; Khajuria R; Bardi GH; Kapoor B; Gupta V
    J Indian Med Assoc; 2006 Jun; 104(6):327-30. PubMed ID: 17058552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anti-tumor necrosis factor alpha therapy in psoriatic arthritis and psoriasis.
    Girolomoni G; Abeni D
    Arch Dermatol; 2001 Jun; 137(6):784-5. PubMed ID: 11405771
    [No Abstract]   [Full Text] [Related]  

  • 25. Etanercept: new preparation. Useful after methotrexate failure in inflammatory rheumatism.
    Prescrire Int; 2003 Aug; 12(66):127-32. PubMed ID: 12906020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do we need new treatment that goes beyond tumor necrosis factor blockers for rheumatoid arthritis?
    Voll RE; Kalden JR
    Ann N Y Acad Sci; 2005 Jun; 1051():799-810. PubMed ID: 16127017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [TNF-alpha inhibitors].
    Fain O
    Rev Prat; 2003 Nov; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract]   [Full Text] [Related]  

  • 28. Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
    Passo M
    Curr Probl Pediatr Adolesc Health Care; 2006 Mar; 36(3):97-103. PubMed ID: 16473286
    [No Abstract]   [Full Text] [Related]  

  • 29. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

  • 31. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
    Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
    [No Abstract]   [Full Text] [Related]  

  • 32. Targeting interleukin-6 in pediatric rheumatic diseases.
    De Benedetti F
    Curr Opin Rheumatol; 2009 Sep; 21(5):533-7. PubMed ID: 19593141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel mechanisms of action of the biologicals in rheumatic diseases.
    Chighizola CB; Favalli EG; Meroni PL
    Clin Rev Allergy Immunol; 2014 Aug; 47(1):6-16. PubMed ID: 23345026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Off-label use of rituximab in systemic rheumatic diseases: case series and review.
    Araújo F; Silva I; Sepriano A; Nero P; Branco JC
    Acta Reumatol Port; 2013; 38(4):290-4. PubMed ID: 24435034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1995 May; 7(3):191-7. PubMed ID: 7612410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1998 May; 10(3):174-8. PubMed ID: 9608318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biologic agents in the therapy of inflammatory rheumatic diseases, including therapeutic antibodies, cytokines, and cytokine antagonists.
    Kalden JR
    Curr Opin Rheumatol; 1994 May; 6(3):281-6. PubMed ID: 8060762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Systemic lupus and biotherapy: 2010 update].
    Arnaud L; Amoura Z
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S296-303. PubMed ID: 21030117
    [No Abstract]   [Full Text] [Related]  

  • 39. Biologic agents in the treatment of inflammatory rheumatic diseases.
    Kalden JR; Manger B
    Curr Opin Rheumatol; 1997 May; 9(3):206-12. PubMed ID: 9204255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapies in pediatric rheumatic diseases.
    Chira P; Sandborg CI
    Curr Opin Pediatr; 2003 Dec; 15(6):579-85. PubMed ID: 14631203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.